PMID- 10886251
OWN - NLM
STAT- MEDLINE
DCOM- 20000809
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 121
IP  - 1
DP  - 2000 Jul
TI  - Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute 
      haemorrhagic immunopneumonitis in a rat model of complement-dependent lung 
      injury.
PG  - 139-45
AB  - Administration of rabbit anti-rat lung serum (PNTS) to rats produces a fulminant 
      haemorrhagic pneumonitis sensitive to the availability of complement. The present 
      experiments were undertaken to assess whether a high dose of IVIG can affect the 
      development of this kind of cytotoxic reaction. The experimental design included 
      groups of Wistar rats pretreated intravenously with physiologic saline, IVIG or a 
      preparation of human F(ab')2 fragments. One hour later the animals were 
      challenged with either saline or PNTS. At 30 min after challenge, blood was 
      collected and the lungs were removed. Pulmonary damage was evaluated by light 
      microscopy; C3 deposits and the binding of immunoglobulins to the alveolar septa 
      were assayed by immunofluorescence. The serum complement activity of the 
      classical and alternative pathways was estimated by a kinetic technique. 
      Pretreatment with IVIG decreased binding of rabbit anti-lung antibodies to 
      alveolar septa and prevented the deposition of C3. These results indicate that 
      pretreatment with IVIG inhibits the binding of the pathogenic antibody to lung 
      tissue. Human IgG binding was not detected in any animal. The protection against 
      lung injury afforded by pretreatment with IVIG, in contrast to the pneumotoxic 
      effect of PNTS observed in control animals, was evident despite the 
      administration of F(ab')2 to the rats. Since pretreatment with F(ab')2 failed to 
      prevent the acute lung lesion, our results indicate that the attenuation afforded 
      by IVIG in this model of complement-dependent tissue injury seems to be related 
      to the integrity of the IgG molecule.
FAU - Dantas, M
AU  - Dantas M
AD  - Department of Clinical Medicine, School of Medicine of Ribeirao Preto, University 
      of Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Costa, R S
AU  - Costa RS
FAU - Barbosa, J E
AU  - Barbosa JE
FAU - Graeff, M S
AU  - Graeff MS
FAU - Sarti, W
AU  - Sarti W
FAU - De Carvalho, I F
AU  - De Carvalho IF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Complement C3)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Antibody Affinity/immunology
MH  - Complement C3/*immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins, Intravenous/*immunology
MH  - Lung/*immunology/pathology
MH  - *Lung Injury
MH  - Pneumonia/*immunology/pathology
MH  - Rabbits
MH  - Rats
MH  - Rats, Wistar
PMC - PMC1905663
EDAT- 2000/07/11 11:00
MHDA- 2000/08/12 11:00
PMCR- 2001/07/01
CRDT- 2000/07/11 11:00
PHST- 2000/07/11 11:00 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 2000/07/11 11:00 [entrez]
PHST- 2001/07/01 00:00 [pmc-release]
AID - cei1252 [pii]
AID - 10.1046/j.1365-2249.2000.01252.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2000 Jul;121(1):139-45. doi: 10.1046/j.1365-2249.2000.01252.x.